Skip to content


PREZCOBIX®: Established Tolerability Profile With a Low Discontinuation Rate1

Safety/Tolerability chart 01

Direct comparisons should not be made between data from separate clinical trials.

  • Selected ADRs (≥Grade 2) occurring in <1% of patients with PREZCOBIX® at Week 24 of Study 130 included fatigue, immune reconstitution syndrome, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, myalgia, abnormal dreams, pruritus, and dyspepsia. There were no differences observed at Week 481

*Excluding laboratory abnormalities as ADRs. ADRs in ≥1% of patients are shown. 
Median exposure.
Mean exposure.

ADRs=adverse drug reactions; OBR=optimized background regimen.

Reference: 1. Data on file. Janssen Therapeutics, Division of Janssen Products, LP.